Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

95.95 -3.83 (-3.84%)

Streaming Delayed Price Updated: 3:54 PM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	638,816
Open	99.26
Bid (Size)	95.92 (300)
Ask (Size)	96.37 (100)
Prev. Close	99.78
Today's Range	95.43 - 100.76
52wk Range	45.91 - 122.20
Shares Outstanding	66,684,077
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗

February 22, 2026

Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.

Via The Motley Fool

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗

February 22, 2026

Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.

Via The Motley Fool

Performance

YTD	-8.6%	-8.6%
1 Month	-6.7%	-6.7%
3 Month	-10.0%	-10.0%
6 Month	-3.3%	-3.3%
1 Year	+75.5%	+75.5%

More News

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Via The Motley Fool

RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March ↗

January 09, 2026

Via Stocktwits

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗

February 22, 2026

Via The Motley Fool

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

February 17, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Prediction: These 3 Stocks Will Crush the Market in 2026 ↗

February 16, 2026

Via The Motley Fool

Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit

February 05, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

This High-Flying Growth Stock Is Hiding in Plain Sight ↗

February 02, 2026

Via The Motley Fool

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

January 09, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

The Great Divergence: Why Big Tech Holds the Line While Logistics and Biotech Face a 2026 Reckoning

December 30, 2025

Via MarketMinute

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

Via MarketMinute

Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder ↗

December 11, 2025

Via Stocktwits

The market is filled with gapping stocks in Thursday's session. ↗

December 11, 2025

Via Chartmill

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

December 11, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Stay updated with the stocks that are on the move in today's after-hours session. ↗

December 10, 2025

Via Chartmill

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

December 10, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

These stocks are moving in today's after hours session ↗

November 11, 2025

Via Chartmill

Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025

November 10, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million ↗

November 08, 2025

Via The Motley Fool

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

November 07, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

November 05, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals (NASDAQ:RYTM) Reports Mixed Q3 2025 Results ↗

November 04, 2025

Via Chartmill

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

November 04, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Rhythm Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Rhythm Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Rhythm Pharmaceuticals, Inc. - Common Stock trade on?

Rhythm Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock is RYTM on the Nasdaq Stock Market

What is the current price of Rhythm Pharmaceuticals, Inc. - Common Stock?

The current price of Rhythm Pharmaceuticals, Inc. - Common Stock is 95.95

When was Rhythm Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Rhythm Pharmaceuticals, Inc. - Common Stock was at 02/23/26 03:54 PM ET

What is the market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock is 6.40B

How many shares of Rhythm Pharmaceuticals, Inc. - Common Stock are outstanding?

Rhythm Pharmaceuticals, Inc. - Common Stock has 6B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.